Our top pick for
PetIQ Inc is a drug manufacturers-specialty & generic business based in the US. PetIQ shares (PETQ) are listed on the NASDAQ and all prices are listed in US Dollars. PetIQ employs 1,015 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$24.61|
|52-week range||$23.52 - $46.00|
|50-day moving average||$25.72|
|200-day moving average||$34.18|
|Wall St. target price||$41.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.58|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-3.11%|
|1 month (2021-09-24)||-0.28%|
|3 months (2021-07-23)||-32.65%|
|6 months (2021-04-23)||-43.02%|
|1 year (2020-10-23)||-19.23%|
|2 years (2019-10-24)||-1.80%|
|3 years (2018-10-24)||32.94|
|5 years (2016-10-20)||N/A|
Valuing PetIQ stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of PetIQ's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
PetIQ's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.6185. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into PetIQ's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
PetIQ's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $57.3 million.
The EBITDA is a measure of a PetIQ's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$851.6 million|
|Operating margin TTM||2.75%|
|Gross profit TTM||$135.2 million|
|Return on assets TTM||1.71%|
|Return on equity TTM||-22.29%|
|Market capitalisation||$745.1 million|
TTM: trailing 12 months
There are currently 3.2 million PetIQ shares held short by investors – that's known as PetIQ's "short interest". This figure is 17.8% up from 2.7 million last month.
There are a few different ways that this level of interest in shorting PetIQ shares can be evaluated.
PetIQ's "short interest ratio" (SIR) is the quantity of PetIQ shares currently shorted divided by the average quantity of PetIQ shares traded daily (recently around 479923.22775264). PetIQ's SIR currently stands at 6.63. In other words for every 100,000 PetIQ shares traded daily on the market, roughly 6630 shares are currently held short.
However PetIQ's short interest can also be evaluated against the total number of PetIQ shares, or, against the total number of tradable PetIQ shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case PetIQ's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 PetIQ shares in existence, roughly 110 shares are currently held short) or 0.1192% of the tradable shares (for every 100,000 tradable PetIQ shares, roughly 119 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against PetIQ.
Find out more about how you can short PetIQ stock.
We're not expecting PetIQ to pay a dividend over the next 12 months.
Over the last 12 months, PetIQ's shares have ranged in value from as little as $23.52 up to $46. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while PetIQ's is 1.4682. This would suggest that PetIQ's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
PetIQ, Inc. operates as a pet medication and wellness company. It operates in two segments, Products and Services. The company offers Rx pet medications, which include heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and co-develops and manufactures its own proprietary value-branded products, as well as distributes third-party branded medications. It also provides OTC medications and supplies primarily within the flea and tick control, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dental treats and nutritional supplements, which comprise hip and joint, vitamins, and skin and coat products. The company provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PetLock, Heart Shield Plus, TruProfen, Betsy Farms, PetAction, Minties, Vera, and Delightibles brands.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.